Biohit Oyj

AGM Information • Jun 23, 2021

Decisions of the Annual General Meeting of Biohit Oyj

Decisions of the Annual General Meeting of Biohit Oyj

Biohit Oyj Decisions of the Annual General Meeting, June 23, 2021 at 3.45 pm
local time (EET)

The Annual General Meeting (AGM) of Biohit Oyj held on Wednesday June 23, 2021
approved the financial statements for the financial year 2020 with a unanimous
decision of the shareholders participating in the AGM. Based on a vote the AGM
decided not to discharge the members of the Board of Directors and the President
and CEO from liability for the financial year 2020. Based on a vote the AGM
decided to approve the Remuneration Report of the company’s Governing Bodies
presented to the AGM; the decision is advisory.

Distribution of dividends

With a unanimous decision of the shareholders participating in the AGM the AGM
resolved in accordance with the proposal of the Board of Directors that no
dividend is paid for the financial period ended on December 31, 2020.

Members of the Board of Directors

Based on a vote the AGM resolved that six (6) members are elected to the Board
of Directors and that professor Osmo Suovaniemi, CEO Franco Aiolfi, emeritus
professor Matti Härkönen, Commercial Counsellor Eero Lehti, Ph.D. Lea Paloheimo
and CEO Liu Feng are elected as members of the Board of Directors until the end
of the next AGM.

Additionally, the AGM resolved based on a vote that the Chairman of the Board of
Directors and the other members of the Board of Directors are paid a meeting fee
of EUR 1,500.

Election of the Auditor and remuneration for the Auditor

With a unanimous decision of the shareholders participating in the AGM the AGM
elected authorized public accountants PricewaterhouseCoopers Oy as the company’s
auditor until the end of the next AGM and that the auditor is paid remuneration
according to invoice approved by the company.

The minutes of the AGM will be available for review by shareholders by Monday
June 28, 2021 on the company’s website (www.biohithealthcare.com/investors) and
at the corporate headquarters of Biohit Oyj, located at Laippatie 1, 00880
Helsinki.

Additional information:
Deputy CEO Osmo Suovaniemi, Biohit Oyj
tel. +358 9 773 861

investor.relations@biohit.fi
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission
is “Innovating for Health” – we produce innovative products and services to
promote research and early diagnosis. Biohit is headquartered in Helsinki,
Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV)
is quoted on Nasdaq Helsinki in the Small cap/Healthcare group.
www.biohithealthcare.com (https://www.globenewswire.com/Tracker?data=ciyb_iZ945H2
z3sK3a9i7Zs03Nkj9jr5Brw7kC1tsoUye5PVgko06PC57Z9BVVT2pXUgp6sn
-tswLd2MUgQOQc8UNXD2BkNm3L02XzRJ7XfJCPaPUqGS1mpI0NZinK5T)